AUPH Q4 2024 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+32.8% YoY

Gross Profit

$54M90.7% margin

Operating Income

-$2M-2.8% margin

Net Income

$1M2.4% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

-11.7%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$30M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$551M

Total Liabilities

$173M

Stockholders' Equity

$377M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$45M	+32.8%
Gross Profit	$54M	$40M	+36.8%
Operating Income	-$2M	-$30M	+94.4%
Net Income	$1M	-$27M	+105.3%

Revenue Segments

Product

$58M100%